David Domzalski - 21 Jan 2025 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: VYNE
Reported as of: 21 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2025, 16:15:05 UTC
Prior SEC filing: 02 Jan 2025
Next SEC filing: 02 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Mutya Harsch, Attorney-in-Fact

Key filing fact

David Domzalski filed Form 4 for VYNE Therapeutics Inc. (VYNE) on 23 Jan 2025.

Key facts

This page summarizes David Domzalski's Form 4 filing for VYNE Therapeutics Inc. (VYNE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2025, 16:15.

Change

Previous filing in this sequence was filed on 02 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +730,000
Change %
Price: $0.000000
Shares after: 730,000
Date: 21 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 730,000
Exercise price: $2.77
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2026 and 6.25% of the shares will vest on the last day of each quarter thereafter. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date.